Correlation Between Acrivon Therapeutics, and AlphaVest Acquisition

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and AlphaVest Acquisition at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and AlphaVest Acquisition into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and AlphaVest Acquisition Corp, you can compare the effects of market volatilities on Acrivon Therapeutics, and AlphaVest Acquisition and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of AlphaVest Acquisition. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and AlphaVest Acquisition.

Diversification Opportunities for Acrivon Therapeutics, and AlphaVest Acquisition

-0.26

Correlation Coefficient

Acrivon Therapeutics,  AlphaVest Acquisition

Very good diversification

The 3 months correlation between Acrivon and AlphaVest is -0.26. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and AlphaVest Acquisition Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AlphaVest Acquisition and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with AlphaVest Acquisition. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AlphaVest Acquisition has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and AlphaVest Acquisition go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and AlphaVest Acquisition

Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to under-perform the AlphaVest Acquisition. In addition to that, Acrivon Therapeutics, is 2.57 times more volatile than AlphaVest Acquisition Corp. It trades about -0.11 of its total potential returns per unit of risk. AlphaVest Acquisition Corp is currently generating about 0.02 per unit of volatility. If you would invest  1,121  in AlphaVest Acquisition Corp on September 12, 2024 and sell it today you would earn a total of  10.00  from holding AlphaVest Acquisition Corp or generate 0.89% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  AlphaVest Acquisition Corp

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

AlphaVest Acquisition

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in AlphaVest Acquisition Corp are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, AlphaVest Acquisition is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Acrivon Therapeutics, and AlphaVest Acquisition

The main advantage of trading using opposite Acrivon Therapeutics, and AlphaVest Acquisition positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, AlphaVest Acquisition can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AlphaVest Acquisition will offset losses from the drop in AlphaVest Acquisition's long position.

The idea behind Acrivon Therapeutics, Common and AlphaVest Acquisition Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.